These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 8841149)

  • 21. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.
    Gawel M; Aschoff J; May A; Charlesworth BR;
    Headache; 2005 Jan; 45(1):7-16. PubMed ID: 15663607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous dihydroergotamine for inpatient management of refractory primary headaches.
    Nagy AJ; Gandhi S; Bhola R; Goadsby PJ
    Neurology; 2011 Nov; 77(20):1827-32. PubMed ID: 22049203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination.
    Schran HF; Bitz DW; DiSerio FJ; Hirsh J
    Thromb Res; 1983 Jul; 31(1):51-67. PubMed ID: 6612697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
    Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T
    J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
    Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
    Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group.
    Gallagher RM
    Arch Neurol; 1996 Dec; 53(12):1285-91. PubMed ID: 8970458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dihydroergotamine nasal spray in the treatment of acute migraine.
    Treves TA; Kuritzky A; Hering R; Korczyn AD
    Headache; 1998 Sep; 38(8):614-7. PubMed ID: 11398305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine.
    Boureau F; Kappos L; Schoenen J; Esperanca P; Ashford E
    Int J Clin Pract; 2000 Jun; 54(5):281-6. PubMed ID: 10954953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dihydroergotamine (DHE) - Then and Now: A Narrative Review.
    Silberstein SD; Shrewsbury SB; Hoekman J
    Headache; 2020 Jan; 60(1):40-57. PubMed ID: 31737909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts.
    Girardin F; Rentsch KM; Schwab MA; Maggiorini M; Pauli-Magnus C; Kullak-Ublick GA; Meier PJ; Fattinger K
    Clin Pharmacol Ther; 2003 Oct; 74(4):341-52. PubMed ID: 14534521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the treatment of migraine. Pharmacokinetic-pharmacodynamic relationships for a programmed release formulation of dihydroergotamine administered orally in the human.
    Aylward M; Davies DE; Maddock J; Robinson PR; Jones M
    Cephalalgia; 1983 Aug; 3 Suppl 1():146-50. PubMed ID: 6616596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine.
    Saper JR; Silberstein S
    Headache; 2006 Nov; 46 Suppl 4():S171-81. PubMed ID: 17078849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DHE in the pharmacotherapy of migraine: potential for a larger role.
    Saper JR; Silberstein S; Dodick D; Rapoport A
    Headache; 2006 Nov; 46 Suppl 4():S212-20. PubMed ID: 17078853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers.
    McAleer SD; Majid O; Venables E; Polack T; Sheikh MS
    J Clin Pharmacol; 2007 Jan; 47(1):13-8. PubMed ID: 17192497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An experimental study on nasal absorption of gentamycin in dogs.
    Wang JQ; Bu GX
    Chin Med J (Engl); 1994 Mar; 107(3):219-21. PubMed ID: 8088184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo approach to determine the route of optimal drug absorption in rats.
    Lhote O; Decoodt A; Moulin A; Dufour A
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():43-6. PubMed ID: 1820918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repetitive dihydroergotamine nasal spray for treatment of refractory headaches: an open-label pilot study.
    Weintraub J
    Curr Med Res Opin; 2006 Oct; 22(10):2031-6. PubMed ID: 17022862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Transformed migraine--chronic daily headache].
    Bøe MG; Monstad P
    Tidsskr Nor Laegeforen; 1999 Nov; 119(29):4311-3. PubMed ID: 10667127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.